Navigation Links
AssureRx Health Raises $12.5 Million Series C Financing
Date:5/30/2012

MASON, Ohio, May 30, 2012 /PRNewswire/ -- AssureRx Health, Inc. today announced the closing of a $12.5 million Series C financing. The personalized medicine company, which provides clinically-relevant information to help physicians select the right drug for individual neuropsychiatric patients, will use the funds to increase commercial activities for its two flagship pharmacogenomic products, GeneSightRx® Psychotropic and GeneSightRx® ADHD, as well as next generation product development activities.

The financing was led by Four Rivers Group and existing investors Claremont Creek Ventures and Sequoia Capital. The financing also included participation of existing investors Cincinnati Children's Hospital Medical Center, Mayo Clinic, CincyTech, Allos Ventures, as well as new investors jVen Capital and Alafi Capital. New investors Four Rivers, jVen Capital, and Alafi Capital bring to AssureRx Health further expertise and partnering connections to help AssureRx Health continue building its leadership position in psychiatric pharmacogenomics.

"Our goal is to build the leading clinical informatics company providing pharmacogenomic and other treatment decision support products to help physicians individualize the treatment of patients with neuropsychiatric and other disorders," said James S. Burns, president and CEO of AssureRx Health. "Proceeds from the Series C financing will be used to expand sales coverage, sponsor multiple clinical studies, and develop new products to help accelerate our leadership position in psychiatric personalized medicine."

Warren Hogarth, partner at Sequoia Capital, said, "AssureRx products have the potential to change the way physicians select the appropriate medications for each of their patients. AssureRx is at the cutting edge of providing treatment decision support products for a very large global psychiatric market. We believe that AssureRx Health is building a world class company."

John Steuart, managing director of Claremont Creek Ventures said, "AssureRx has enormous potential to lead the transformation of neuropsychiatric care toward personalized patient treatment. GeneSightRx Psychotropic, GeneSightRx ADHD and future pharmacogenomic products hold the promise for faster, better patient outcomes and less costly care. We believe that AssureRx products have the potential for significant adoption by the psychiatric community, leading ultimately to incorporating pharmacogenomics into routine psychiatric practice guidelines."

From a simple cheek swab, the GeneSightRx technology measures and analyzes clinically important genetic variants that determine how a patient's unique genetic make-up affects his or her ability to tolerate or effectively respond to psychotropic medications. Patient-specific genetic information obtained through GeneSightRx can assist physicians in the process of selecting appropriate antidepressant and antipsychotic medications for individual patients.

About Claremont Creek Ventures 
Claremont Creek Ventures (CCV) is a seed and early stage venture firm. CCV invests in digital healthcare, energy technology, payments/commerce, and online businesses.  Utilizing the firm's proprietary life-cycle venturing program, Claremont Creek Ventures also partners with entrepreneurs and institutions, including UC Berkeley, Lawrence Livermore Labs, Stanford University and UC Davis. Claremont Creek has more than $300 million in capital under management in two funds. CCV's digital healthcare investments in addition to AssureRx Health include Genalyte, GeneWeave, GigaGen, Fluxion Biosciences, Natera, Tibion and Zipline Medical. For more information, visit www.claremontcreek.com.

About Sequoia Capital 
Sequoia Capital provides venture capital funding to founders of startups who want to turn business ideas into enduring companies. As the "Entrepreneurs Behind the Entrepreneurs", Sequoia Capital's Partners have worked with innovators such as Steve Jobs of Apple Computer, Larry Ellison of Oracle, Bob Swanson of Linear Technology, Sandy Lerner and Len Bozack of Cisco Systems, Dan Warmenhoven of NetApp, Jerry Yang and David Filo of Yahoo!, Jen-Hsun Huang of NVIDIA, Michael Marks of Flextronics, Larry Page and Sergey Brin of Google, Chad Hurley and Steve Chen of YouTube, Dominic Orr and Keerti Melkote of Aruba Networks, Tony Hsieh of Zappos, Omar Hamoui of Admob, Steve Streit of Green Dot and Reid Hoffman and Jeff Weiner of LinkedIn. To learn more about Sequoia Capital visit www.sequoiacap.com/us.

About AssureRx Health 
AssureRx Health, Inc. is a personalized medicine company specializing in pharmacogenomics and is dedicated to helping physicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The GeneSightRx analysis is based on pharmacogenomics, the study of the genetic factors that influence an individual's response to drug treatments, FDA approved manufacturers' drug labels, scientific and clinical peer-reviewed publications, and proven pharmacology. Cincinnati Children's Hospital Medical Center and Mayo Clinic are equity holders and technology collaborators. To learn more about pharmacogenomics and GeneSightRx, please click here.

Contacts: 
James S. Burns
President & CEO 
AssureRx Health, Inc. 
(513) 234-0510 
e-mail: jburns@assurerxhealth.com

Troy May
Marketing Communications Manager 
AssureRx Health, Inc.  
(513) 234-0510 
e-mail: tmay@assurerxhealth.com  


'/>"/>
SOURCE AssureRx Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth
2. AssureRx Expands GeneSightRx® Pharmacogenetic Profile with Sixth Gene to Enhance Guidance of Psychiatric Drug Prescribing
3. AssureRx Health Raises $11 Million Series B Financing
4. Medco Research Institute® and AssureRx Health Initiate Pilot Program to Evaluate Adoption and Clinical Impact of Pharmacogenetic Testing for Selection of Psychotropic Medications
5. AssureRx Health Launches Personalized Medicine Test for ADHD
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Tone Deafness Explained, from the Harvard Health Letter
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Frontier Pharma: ... Commercializing First-in-Class Innovation Chronic Obstructive ... with chronic inflammation of the airways and lungs. ... symptoms make the disease one of the leading ... death in the world. COPD is linked to ...
(Date:2/4/2016)... COLUMBUS, Ohio, Feb. 4, 2016 Mettler-Toledo International ... results for 2015.  Provided below are the highlights: ... the quarter compared with the prior year.  Reported sales ... in the quarter. , Net earnings per diluted ... in the prior- year period.  Adjusted EPS was $4.65, ...
(Date:2/4/2016)... 4, 2016 In response to the opioid abuse ... Commissioner for Medical Products and Tobacco, along with other FDA ... agency,s approach to opioid medications. The plan will focus on ... in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ensure that ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... ... After years as an active staff surgeon and having served as the director ... transitioned to chief of the Division of Plastic Surgery at what is now known ... began a second three-year term in January of 2016. , The original selection was ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. ... Annual No Cost Dental Day to individuals in need. The event is scheduled to ... No Cost Dental Day is to provide dental care to community members in need. ...
(Date:2/5/2016)... ... 05, 2016 , ... Health and wellness is a topic that should concern ... they are experiencing an illness. Migraines are a severe form of a headache and ... would not wish the pain on their worst enemy, the feeling can last for ...
(Date:2/5/2016)... ... 05, 2016 , ... –This week, Atascadero water heater company First Call ... heater. To view the report, click here or see below. , ... their pros and cons, the type chosen is almost entirely up to personal preference. ...
Breaking Medicine News(10 mins):